{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:00Z","timestamp":1787169900192,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"\n Context:<\/jats:title>\n Coronavirus disease (COVID-19) has led to over 2,589,638 deaths globally as of March 2021 and speedy discovery of vaccines. Nigeria started the phase one COVID-19 vaccination in March 2021 using the Oxford AstraZeneca vaccine. Reports of severe adverse events with the Oxford AstraZeneca vaccine resulted in its suspension in some countries necessitating the need to determine its safety.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n To assess the prevalence, types and severity of the adverse events following COVID-19 vaccination in Rivers State, Nigeria.<\/jats:p>\n <\/jats:sec>\n \n Settings and Design:<\/jats:title>\n A cross-sectional study design was adopted.<\/jats:p>\n <\/jats:sec>\n \n Subjects and Methods:<\/jats:title>\n Simple random sampling method was used to select a total of 428 adults from recipients of the first dose of COVID-19 vaccine within 28 days of vaccination. A questionnaire adapted from World Health Organisation was interviewer-administered through phone calls; responses were recorded on Kobo Toolbox.<\/jats:p>\n <\/jats:sec>\n \n Statistical Analysis Used:<\/jats:title>\n \n Descriptive analysis of variables was done and the association between adverse events and age, allergy and medical history were determined. The level of statistical significance was predetermined at a\n P<\/jats:italic>\n < 0.05.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n In this study, 50.5% of respondents reported post-vaccination adverse events out of which 10 (4.6%) were severe (30% of the severe cases were life-threatening, 60% were hospitalised and 10% were placed on bed rest). The most common side effects were fever (73.0%), pain at the injection site (41.2%), fatigue (33.3%), body ache (17.5%) and headache (13.8%). No significant association was observed between the incidence of severe adverse events and participants with allergies or medical history.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The adverse events associated with the COVID-19 vaccine were largely mild and resolved within a few days. Further research is required to classify adverse events into categories.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/npmj.npmj_11_22","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T05:25:40Z","timestamp":1681363540000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Adverse Events Following COVID-19 Vaccination in Rivers State, Nigeria"],"prefix":"10.4103","volume":"29","author":[{"given":"Agiriye Monima","family":"Harry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement Kevin","family":"Edet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyarawo Effiong","family":"Ekanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinonye Judith","family":"Kemdirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abasianam Etuk","family":"Uduak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240908","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat Microbiol"},{"key":"R2-3-20240908","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","article-title":"A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: Lessons from other pathogenic viruses","volume":"9","author":"Fung","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R3-3-20240908","doi-asserted-by":"crossref","first-page":"138996","DOI":"10.1016\/j.scitotenv.2020.138996","article-title":"Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency","volume":"730","author":"Acter","year":"2020","journal-title":"Sci Total Environ"},{"key":"R4-3-20240908","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"R5-3-20240908","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-3-20240908","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"R8-3-20240908","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.2020.6130","article-title":"Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China","volume":"323","author":"Pan","year":"2020","journal-title":"JAMA"},{"key":"R9-3-20240908","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"R10-3-20240908","first-page":"e7560","article-title":"A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19)","volume":"12","author":"Kakodkar","year":"2020","journal-title":"Cureus"},{"key":"R11-3-20240908","first-page":"21","article-title":"Modelling the spread of COVID-19 with impact of awareness and medical assistance","volume":"10","author":"Agaba","year":"2020","journal-title":"Math Theor Model"},{"key":"R12-3-20240908","doi-asserted-by":"crossref","first-page":"606801","DOI":"10.3389\/fpubh.2021.606801","article-title":"Self-medication practices and associated factors in the prevention and\/or treatment of COVID-19 virus: A population-based survey in Nigeria","volume":"9","author":"Wegbom","year":"2021","journal-title":"Front Public Health"},{"key":"R14-3-20240908","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse events reported from COVID-19 vaccine trials: A systematic review","volume":"36","author":"Kaur","year":"2021","journal-title":"Indian J Clin Biochem"},{"key":"R15-3-20240908","doi-asserted-by":"crossref","first-page":"51","DOI":"10.9734\/ijtdh\/2020\/v41i1330347","article-title":"Preparedness for COVID-19 by primary healthcare workers in Rivers State, Nigeria: Facility cross-sectional survey","volume":"41","author":"Edet","year":"2020","journal-title":"Int J Trop Diseases Health"},{"key":"R16-3-20240908","doi-asserted-by":"crossref","first-page":"102873","DOI":"10.1016\/j.agsy.2020.102873","article-title":"Editorial: Impacts of COVID-19 on agricultural and food systems worldwide and on progress to the sustainable development goals","volume":"183","author":"Stephens","year":"2020","journal-title":"Agric Syst"},{"key":"R17-3-20240908","first-page":"56","article-title":"Effect of Covid-19 lockdown on farmers in Rivers State, Nigeria: Positive perspective","volume":"38","author":"Anagah","year":"2020","journal-title":"Asian J Agric Ext Econ Sociol"},{"key":"R18-3-20240908","doi-asserted-by":"crossref","first-page":"8438","DOI":"10.3390\/su12208438","article-title":"Impacts of the COVID-19 pandemic on life of higher education students: A global perspective","volume":"12","author":"Aristovnik","year":"2020","journal-title":"Sustainability"},{"key":"R19-3-20240908","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jad.2020.08.001","article-title":"Impact of COVID-19 pandemic on mental health in the general population: A systematic review","volume":"277","author":"Xiong","year":"2020","journal-title":"J Affect Disord"},{"key":"R20-3-20240908","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"R22-3-20240908","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijid.2020.06.067","article-title":"Coronavirus outbreak in Nigeria: Burden and socio-medical response during the first 100 days","volume":"98","author":"Amzat","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R23-3-20240908","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3390\/ijerph17093054","article-title":"Early transmission dynamics of novel coronavirus (COVID-19) in Nigeria","volume":"17","author":"Adegboye","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R24-3-20240908","first-page":"7192","article-title":"Forecasting the spread of COVID-19 in Nigeria using Box-Jenkins modeling procedure","volume":"17","author":"Ibrahim","year":"2020","journal-title":"medRxiv"},{"key":"R25-3-20240908","first-page":"146","article-title":"Covid-19 in Ekiti State Nigeria: Why should we worry","volume":"7","author":"Oluwatuyi","year":"2020","journal-title":"Int J Res Sci Innov"},{"key":"R26-3-20240908","doi-asserted-by":"crossref","first-page":"230","DOI":"10.11604\/pamj.2021.38.230.27325","article-title":"When it is available, will we take it? Social media users' perception of hypothetical COVID-19 vaccine in Nigeria","volume":"38","author":"Adebisi","year":"2021","journal-title":"Pan Afr Med J"},{"key":"R27-3-20240908","first-page":"2630","article-title":"The implications and impact of Covid-19 preventive measures in Nigeria: A case of Port-Harcourt city and Obio\/ Akpor Local Governments in Rivers State (March 2020\u2013August 2020)","volume":"3","author":"Chinnah","year":"2020","journal-title":"Jos J Relig Philos"},{"key":"R28-3-20240908","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4236\/odem.2021.91003","article-title":"Prevalence and pattern of COVID-19 among healthcare workers in Rivers State Nigeria","volume":"9","author":"Alasia","year":"2021","journal-title":"Occup Diseases Environ Med"},{"key":"R29-3-20240908","first-page":"1","article-title":"COVID-19 outbreak situation in Nigeria and the need for effective engagement of community health workers for epidemic response","volume":"2","author":"Ajisegiri","year":"2020","journal-title":"Global Biosecurity"},{"key":"R31-3-20240908","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4269\/ajtmh.21-0033","article-title":"Contact tracing and the COVID-19 response in Africa: Best practices, key challenges, and lessons learned from Nigeria, Rwanda, South Africa, and Uganda","volume":"104","author":"Nachega","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"R32-3-20240908","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.18203\/2394-6040.ijcmph20211733","article-title":"Predictors of acceptance of Covid-19 vaccine among patients at a tertiary hospital in South-South Nigeria","volume":"8","author":"Allagoa","year":"2021","journal-title":"Int J Community Med Public Health"},{"key":"R33-3-20240908","doi-asserted-by":"crossref","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 vaccine: A comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res"},{"key":"R34-3-20240908","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jib-2021-0002","article-title":"Super-rapid race for saving lives by developing COVID-19 vaccines","volume":"18","author":"Uttarilli","year":"2021","journal-title":"J Integr Bioinform"},{"key":"R35-3-20240908","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3126\/jpahs.v8i1.36242","article-title":"Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal","volume":"8","author":"Shrestha","year":"2021","journal-title":"J Patan Acad Health Sci"},{"key":"R36-3-20240908","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.vaccine.2020.02.046","article-title":"Immunization stress-related response \u2013 Redefining immunization anxiety-related reaction as an adverse event following immunization","volume":"38","author":"Gold","year":"2020","journal-title":"Vaccine"},{"key":"R37-3-20240908","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","article-title":"Assessment of causality of individual adverse events following immunization (AEFI): A WHO tool for global use","volume":"31","author":"Tozzi","year":"2013","journal-title":"Vaccine"},{"key":"R38-3-20240908","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"R40-3-20240908","first-page":"1","article-title":"Adverse event terminology","volume":"8","author":"Goldfarb","year":"2012","journal-title":"J Clin Res Best Pract"},{"key":"R41-3-20240908","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2008.04.019","article-title":"Physician's guide to pharmacovigilance: Terminology and causality assessment","volume":"20","author":"Rehan","year":"2009","journal-title":"Eur J Intern Med"},{"key":"R42-3-20240908","doi-asserted-by":"crossref","first-page":"D66","DOI":"10.1016\/j.vaccine.2015.09.035","article-title":"Vaccine hesitancy: Causes, consequences, and a call to action","volume":"33","author":"Salmon","year":"2015","journal-title":"Vaccine"},{"key":"R43-3-20240908","first-page":"10","article-title":"The complicated task of monitoring vaccine safety","volume":"112","author":"Ellenberg","year":"1997","journal-title":"Public Health Rep"},{"key":"R48-3-20240908","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/vaccines9060556","article-title":"Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study implementing machine learning for predicting severity of side effects","volume":"9","author":"Hatmal","year":"2021","journal-title":"Vaccines (Basel"},{"key":"R49-3-20240908","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.3346\/jkms.2021.36.e114","article-title":"Adverse events following immunization associated with coronavirus disease 2019 vaccination reported in the mobile vaccine adverse events reporting system","volume":"36","author":"Jeon","year":"2021","journal-title":"J Korean Med Sci"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_11_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:38Z","timestamp":1787166878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_11_22"}},"subtitle":["A Cross-Sectional Study"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_11_22","relation":{},"ISSN":["1117-1936"],"issn-type":[{"value":"1117-1936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}